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DNA/RNA 
The establishment of an in vitro assay to screen for 
active transformation of mouse NIH 3T3 fibroblasts 
has revealed transforming genes identified as human 
homologs of Harvey or Kirsten murine sarcoma virus 
oncogenes (v-Ha-ras, or v-Ki-ras, respectively). 
Thereupon, an additional transforming gene was found 
in human neuroblastoma and fibrosarcoma cell lines 
that has been identified as the third functional memb r 
of the ras gene family. This gene have been termed N-
ras. Thus, the human ras family consists of three poto-
oncogenes, c-Harvey (H)-ras, c-Kirsten (K)-ras, andN-
ras, no c-prefix was added because no viral counterpart 
was found. Additionally, genes were found in the 
genome of human and other mammalian species that 
display high homology to the functional ras genes but 
lack intervening sequences (introns). These genes were
identified as processed and inactivated pseudogenes. 
Functional ras genes differ greatly in length due to 
large differences in the size of their introns ranging 
from about 6kb to 50kb, but they each have 4 coding 
exons. The human K-ras gene contain an alternative 
fourth coding exon. Alternative RNA splicing specifies 
either of two isomorphic proteins differing by 25 amino 
acid residues at their carboxy-terminus. Ras genes ar  
expressed in all tissues, have a promotor region with
multiple GC boxes, but lack a TATA- or CCAT-box; 
features resembling the promotors of housekeeping 
genes (Lowndes et al., 1999). 
A comparison of human H-, K-, and N-ras nucleotide 
sequences with the corresponding regions in other 
mammalian species reveals a remarkable sequence 
similarity (Watzinger et al., 1998). All differences are 
synonymous changes with no effect on the amino acid  
sequence of RAS proteins, indicating a strong 
evolutionary pressure on the amino acid sequence of 
these genes. 
The ras oncogenes in various human tumors harbor 
point mutations that confer transforming activity. 
Mutations leading to an amino acid substitution at the 
positions 12, 13, and 61 are the most common in 
naturally occurring (i.e. non-experimental) (Kiaris and 
Spandidos, 1999) neoplasms and experimentally 
induced animal tumors (Mangues and Pellicer, 1992; 
Stanley, 1995) (see following sections). 
In addition to the most frequent mechanism of point-
mutational activation, overexpression of non-mutated 
ras genes can also convert normal ras genes into 
oncogenes. The increased amount of the corresponding 
mRNA derives either from high transcriptional activity 
of heterologous promotors and enhancers (Chakraborty 
et al., 1991) or results from amplified ras genes located 
either intrachromosomally as homogeneously staining 
regions or extrachromosomally as double minute 
chromosomes (Nishimura and Sekiya, 1987). 
Functional aspects of RAS proteins 
Mammalian ras genes code for closely related, small 
proteins of 189 amino acids with a molecular weight of 
21,000 Daltons (p21). When the alternative exon of H- 
or K-ras is used, proteins of 170 or 188 amino acids are 
synthesized. The molecular weight of the H-ras protein 
variant is 19,000 Daltons and that of the K-ras variant 
is not distinguishable from the normal RAS proteins. 
RAS proteins are localized in the inner plasma 
membrane, bind GDP and GTP and possess an intrinsic 
GTPase activity, implicated in the regulation of their 
activity. Because of the functional resemblance to G-
Proteins, p21RAS  
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Figure 1 Mechanism of RAS regulation. 
 
have been hypothesized to be also involved in different 
types of ligand-mediated signal transduction pathways. 
Later, RAS proteins were shown to influence 
proliferation, differentiation, transformation, and 
apoptosis by relaying mitogenic and growth signals into
the cytoplasm and the nucleolus (Khosravi Far and Der,
1994). In a normal cell most of the RAS molecules are 
present in an inactive GDP-bound conformation. An 
extracellular stimulus init iates the release of 
GDP and the subsequent binding of GTP. This 
conformational change enables the interaction with the 
putative effector molecules and permits the transmis ion 
of signals. Finally, the active GTP-bound state is turned 
off by hydrolysis of GTP to GDP and inorganic 
phosphate. 
The intrinsic GTPase activity is rather weak, not 
sufficiently effective for signal transduction pathways 
where rapid inactivation is required. In order to 
accelerate this low rate of hydrolysis (which is about 
10-2 min-1) and to enable a transient burst of signalling 
activity, regulatory proteins like GAPs (GTPase 
activating proteins) (Ahmadian et al., 1996) or NF-1 
(Neurofibromatosis Type 1) protein (McCormick, 
1995), bind to the GTP-containing conformation and 
stimulate the GTPase activity more than 100-fold. The 
decreasing level of RAS-GTP, and hence, increasing 
level of RAS-GDP complexes result in a loss of the 
biological activity of RAS (see Fig. 1). In a normal cell, 
GAPs help to keep most of p21RAS in an inactive 
GDP-bound state. The finding that overexpression of 
non-mutated ras genes can also transform cells supports 
the idea that the abundance of GAPs is limited. 
Overexpression of p21RAS could lead to saturation of 
the regulatory proteins, resulting in a constitutive, 
deregulated activation of RAS proteins and oncogenic 
transformation. 
Another group of regulatory proteins involved in 
stimulating the transition of RAS proteins from the 
inactive- to the active GTP-bound state are designated 
Guanine Nucleotide Exchange Factors (GEFs) or RAS-
GRFs (guanine nucleotide releasing factors) (Satoh nd 
Kaziro, 1992). Normally, the release of GDP is 
regulated by the intracellular concentration of GTP. An 
increase in the GTP concentration leads to an enhanced 
dissociation of GDP. GEFs catalyze the dissociation of 
GDP (see Fig.1). A ligand-free RAS protein 
immediately binds GTP, because it is 10-fold more 
abundant in the cytosol than GDP. 
The activity of RAS proteins is regulated by a cycle of 
guanine nucleotide binding and hydrolysis. In the 
active state p21 is bound to GTP, in the inactive to 
GDP. GEF (Guanine Nucleotide Exchange Factor) 
promotes dissociation of GDP and acts as a positive 
regulator; GAP (GTPase activating protein) promotes 
hydrolysis of GTP and acts as a negative regulator. Pi, 
inorganic phosphate. 
Structure of RAS proteins 
The alignment of their primary amino acid sequence 
clearly indicates the presence of four domains within 
the RAS molecules. The first domain includes 85 
amino acids at the N-terminus which are found to be 
identical in H-, K-, and N-ras, demonstrating a high 
degree of conservation. The following 80 amino acids 
form a second domain, showing less conservation (70-
80%) within the RAS proteins. The third domain spans 
the rest of the molecule, except for the last four amino 
acids, and represents a hypervariable region.  




Figure 2 Topological structure of p21. 
 
The highly conserved carboxy-terminal motif CAAX 
(where C stands for cysteine, A for any aliphatic 
residue, and X for any uncharged amino acid) is the 
result of posttranslational modifications and forms the 
last domain. 
For more accurate identification of biologically relevant 
regions of p21RAS and for the interpretation of 
activating mutations, X-crystallographic analysis of
GDP- and GTP-bound RAS molecules and in vitro 
mutagenesis studies with mutated or truncated RAS 
proteins were performed. As a result of these studies, 
the catalytic domain was identified between residues 1 
to 171, including the region involved in guanine 
nucleotide binding where residues 10-16 and 56-59 
interact with b- and c-phosphate, and residues 116-119 
and 152-165 interact with the guanine base. The so 
called core effector region (located between residues 
32-40), represents an essential element for all 
interactions with putative downstream effectors andthe 
GAPs. A region encompassing the last four amino acids 
at the C-terminus (residues 186-189), was shown to be 
essential for the attachment of p21RAS to the plasma 
membrane.  
Comparison of the crystal structure of RAS-GTP (as 
indicated in Fig.2) and RAS-GDP complexes revealed 
that switching between the active and the inactive state 
is associated with a conformational change of two 
regions, designated as switch I (residues 30-38), 
overlapping with the core effector region, and switch II 
(60-76). Binding of the neutralizing antibody Y13-259 
to residues 63-73, inhibits the GTP-GDP change, 
indicating that this conformational change is necessary 
for the transition of RAS from the GDP- to the GTP-
bound state and vice versa (Milburn et al., 1990; 
Scheffzek et al., 1997). 
The polypeptide chain of RAS p21 consists of six b-
strands and five a-helices. Loop 1, alias phosphate-
binding (P-) loop (residues 10 to 16), switch regions I 
(30 to 37), including loop 2 with adjacent residues, and 
II (60 to 67), including loop 4 and a-helix 2, reprsent 
the active center of the molecule and are involved in 
the binding interaction between p21RAS and GTP. N 
stands for the amino terminal, C for the carboxy 
terminal end (modified figure reprinted from Seminars 
in Cancer Biology vol 3, (4), F Wittinghofer, Tree-
dimentional structure of p21H-ras and its implications, 
p189-198, 1992, by permission of the publisher 
Academic Press). 
Activating point mutations have been localized in 
codons 12, 13, 59, 61, 63, 116, 117, 119, and 146 
(Barbacid, 1990). All of these alterations occur at or 
near the guanine nucleotide binding sites. The effects 
of point mutations are either reduced GTPase activity 
(if amino acids 12, 13, 59, 61, 63 are involved), so that 
oncogenic RAS mutants are locked in the active GTP-
bound state, or decreased nucleotide affinity, and 
hence, increased exchange of bound GDP for cytosolic 
GTP (if amino acids 116, 117, 119 or 146 are affected). 
The inefficient deactivation of the active GTP-bound 
RAS proteins is intensified by the inability of GAPs to 
stimulate the conversion to the inactive, GDP-bound 
state. All point mutations cause an accumulation of 
activated RAS-GTP complexes, leading to continuous 
signal transduction by facilitating accumulation of
constitutively active, GTP-bound RAS protein, and 
thus contributing to a malignant cell phenotype. 
Incidence of ras mutations  
(See also the appendix). 
Activating ras mutations can be found in human 
malignancies with an overall frequency of 15-20%. A 
high incidence of ras gene mutations has been reported 
in malignant tumors of the pancreas (80-90%, K-ras)  
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(Ballas et al., 1988; Smit et al., 1988), in colorectal 
carcinomas (30-60%, K-ras) (Breivik J et al., 1994; 
Spandidos et al., 1996), in non-melanoma skin cancer 
(30-50%, H-ras) (Barbacid, 1990; Rodenhuis, 1992), in 
hematopoietic neoplasia of myeloid origin (18-30%, K-
and N-ras) (Breivik et al., 1994; Nakagawa et al., 1992; 
Neubauer et al., 1994; Satoh and Kaziro, 1992), and in 
seminoma (25-40%, K-ras) (Mulder et al., 1989; 
Ridanpaa et al., 1993). In other tumors, a mutant rs 
gene is found at a lower frequency: for example, in 
breast carcinoma (0-12%, K-ras) (Rochlitz et al., 1989; 
Spandidos, 1987), glioblastoma and neuroblastoma (0-
10%, K- and N-ras) (Ballas et al., 1988; Brustle et al., 
1996; Ireland, 1989). 
Appendix: RAS mutations in various cancers and bibliography 
 
H-RAS mutations 
Tumor Frequency (%) References 
Stomach  0-40  (Deng et al., 1991; Kim et al., 1997; Miki et al., 1991; Nanus et al., 
1990; Victor et al., 1990)  
Urinary Bladder  0-65  (Hong et al., 1996; Malone et al., 1985; Olderoy et al., 1998; Saito et 
al., 1997; Visvanathan et al., 1988)  
Prostate  0-10  (Carter et al., 1990; Gumerlock et al., 1991; Konishi et al., 1997; 
Shiraishi et al., 1998)  
Skin  0-45  (Campbell et al., 1993; Tormanen and Pfeifer, 1992)  
Thyroid  0-60  (Bouras et al., 1998; Capella et al., 1996; Fusco et al., 1987; Lemoine 
et al., 1988; Lemoine et al., 1989; Suarez et al., 1988)  
Breast  0-10  (Kraus et al., 1984; Spandidos, 1987)  
Head and neck  0-30  (Clark et al., 1993; Kiaris et al., 1995; Rumsby et al., 1990; Saranath et 
al., 1991)  
Endometrium  5  (Varras et al., 1996)  
K-RAS mutations 
Tumor Frequency (%) Reference 
Pancreas  80-90  (Almoguera et al., 1988; Smit et al., 1988; Watanabe et al., 1996)  
Colon and rectum  25-60  (Boughdady et al., 1992; Breivik et al., 1994; Burmer et al., 1991; 
Halter et al., 1992; Kojima et al., 1997; Oudejans et al., 1991; 
Spandidos et al., 1996; Ward et al., 1998; Yamagata et al., 1994)  
Lung  25-60  (Husgafvel-Pursiainen et al., 1992; Rodenhuis and Slebos, 1992; 
Rodenhuis et al., 1997; Sagawa et al., 1998; Suzuki et al., 1990)  
Prostate  0-25  (Capella et al., 1991; Carter et al., 1990; Gumerlock et al., 1991; 
Konishi et al., 1992; Konishi et al., 1997; Shiraishi et al., 1998)  
Skin  0-25  (Albino et al., 1991; Shukla et al., 1989)  
Thyroid  0-60  (Capella et al., 1996; Fusco et al., 1987; Lemoine et al., 1988; Lemoine 
et al., 1989; Suarez et al., 1988)  
Liver  10-25  (Challen et al., 1992; Marion et al.,1991; Tada et al., 1990; Tada et al., 
1992)  
Ovary  0-50  (Enomoto et al., 1991; Ichikawa et al., 1994; Teneriello et al., 1993)  
Endometrium  10-40  (Duggan et al., 1994; Enomoto et al., 1991; Ignar-Trowbridge et al., 
1992; Mizuuchi et al., 1992; Sasaki et al., 1993; Semczuk et al., 1997; 
Varras et al., 1996)  
Kidney  0-50  (Nagata et al., 1990; Skalkeas et al., 1991)  
Brain  0-15  (Ballas et al., 1988; Ballas et al., 1988; Brustle et al., 1996; Ireland, 
1989; Maltzman et al., 1997)  
Testis 
(Seminoma)  
10-45  (Moul et al., 1992; Mulder et al., 1989; Ridanpaa et al., 1993)  
Leukemia 
(ANLL, MDS)  
5-15  (Nakagawa et al., 1992; Neubauer et al., 1994; Padua et al., 1998; Sheng 
et al., 1997)  
Urinary Bladder  5  (Olderoy et al., 1998)  
Head and neck  10  (Rathcke et al., 1996; Rumsby et al., 1990)  
Breast  10  (Dawson et al., 1996)  
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N-RAS mutations  
Tumor Frequency (%) Reference 
Leukemia ANLL, 
MDS  
20-40  (De Melo et al., 1997; Nakagawa et al., 1992; Neubauer et al., 1994; 




0-10  (Watzinger et al., 1994; Yokota et al., 1998)  
Brain  0-15  (Ballas et al., 1988; Bos, 1988; Brustle et al., 1996; Ireland, 1989; 
Maltzman et al., 1997)  
Skin  0-20  (Albino et al., 1984; Mooy et al., 1991; Soparker et al., 1993; van't 
Veer et al., 1989)  
Thyroid  0-60  (Capella et al., 1996; Fusco et al., 1987; Lemoine et al., 1988; Lemoine 
et al., 1989; Suarez et al., 1988)  
Testis  0-40  (Moul et al., 1992; Mulder et al., 1989; Ridanpaa et al., 1993)  
Stomach  (gastric tumors) 5 (Kim et al., 1997)  
Liver  0-15  (Challen et al., 1992; Tada et al., 1990; Tada et al., 1992)  
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